Gene synthesis and vector construct design for Chimeric Antigen Receptor (CAR-T) and T-cell Receptor (TCR-T) therapies require specific planning for German and EU clinical evaluation. Key areas of focus include mitigating immunogenicity through sequence optimization and selecting appropriate vector platforms. The objective is to build a robust data package supporting Investigational Medicinal Product Dossier (IMPD) submissions for Advanced Therapy Medicinal Products (ATMPs).
Frequently Asked Questions
Q: What are the primary considerations for gene synthesis when developing CAR-T or TCR-T constructs for EU clinical trials?
For EU submissions, the focus is on minimizing potential immunogenicity and ensuring stable, predictable expression. This involves comprehensive codon optimization for human cell expression, removal of cryptic splice sites, and elimination of sequences that could trigger innate immune responses. A robust synthesis process is foundational for a successful IMPD application for an ATMP.
Q: How does Franklin Biolabs support multi-jurisdictional submissions for somatic cell therapies developed in Germany?
We align vector design and analytical development with harmonized international guidelines (ICH). Our process supports the generation of a core data package suitable for concurrent submissions to regulatory bodies like the Paul-Ehrlich-Institut (PEI), the EMA, and the FDA, streamlining the path to global clinical trials.
Q: What is the typical timeline for advancing a cell therapy candidate to the clinical stage with your support?
Our integrated approach to vector design, preclinical toxicology, and analytics typically enables sponsors to move from a candidate to a successful IND or IMPD submission within an 18-24 month timeline. This accelerated path is supported by the deep institutional knowledge of our core scientific team.
Gene Synthesis and Vector Design for German TCR-T and CAR-T Programs
Proven Intelligence in Somatic Cell Therapy Constructs.
The design of the synthetic gene construct is a foundational step in the development of any CAR-T or TCR-T therapeutic. For programs targeting clinical evaluation in Germany and the broader European Union, this process requires a specific focus on mitigating biological risk and aligning with the stringent regulatory expectations for ATMPs. The objective is to produce a construct that ensures potent anti-tumor activity while minimizing the potential for host immune rejection or unforeseen toxicities.
A tailored preclinical strategy begins with the genetic sequence. Key optimization steps include:
* Codon Optimization: Adapting the transgene sequence for optimal expression in human T-cells without altering the final amino acid sequence.
* Sequence Analysis: Identifying and removing potential immunogenic epitopes, cryptic splice sites, or premature polyadenylation signals that could compromise construct integrity and function.
* Vector Backbone Selection: Choosing an appropriate viral vector, typically a lentiviral (LV) platform for stable integration, or non-viral systems for specific gene editing applications.
Mitigating Immunogenicity Risk at the Sequence Level
The potential for an immune response against the therapeutic transgene is a known liability that can lead to the elimination of engineered T-cells and a loss of clinical efficacy. High-level findings from preclinical research in other vector systems underscore this translational challenge. Work in nonhuman primates has demonstrated that even with established AAV vectors, a robust transgene-specific T-cell response can ablate expression (PMID: 19441963). Similarly, studies with lentiviral vectors have shown that transgene-specific T-cell activation is a primary driver for the loss of transduced cells over time (PMID: 19724265).
These principles directly inform our approach to designing CAR and TCR constructs. By proactively engineering sequences to be less immunogenic, we reduce the risk of immune-mediated clearance, a de-risking step for advancing into human trials.
This de-risking strategy is supported by integrated scientific and operational teams with extensive expertise in vector biology, production, and the development of robust analytical packages.
Our scientific leadership and core operational team carry forward a track record that includes a 100% successful IND rate since 2019. While Franklin Biolabs was formally launched in 2024, this history of success provides the proven intelligence necessary to navigate complex biological and regulatory challenges for next-generation therapies.
This rigorous, science-first approach to gene synthesis and vectorology provides the robust foundation required for a successful IMPD submission and subsequent clinical evaluation in Germany.
For more information on our comprehensive vector services, please see our main service portal.
Vector | CMC | Analytics Services
